do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Acute inhibition modulates vascular tone through independent pathways Safety of SGLT2 inhibitors, DPP-4

Discontinue these medications at least 2 months before attempting conception to allow clearance from the body

A five-month treatment with PEGylated exenatide (NLY01) was found to decrease the secretion of complement 1q (C1q), IL-1, and TNF- by primary mouse microglia, thereby limiting the conversion of astrocytes to a neurotoxic phenotype

Clinicians should consider taking patients off these drugs if they develop signs of heart failure

Krishnamurthy Clinical Research Coordinator, South Asia A clearly defined documentation pathway and upfront compliance screening supported a structured and transparent internal approval process. R

Given the heterogeneity among GLP-1RAs in terms of pharmacokinetic profiles, therapeutic efficacy, adverse event rates, and dosing regimens, each agent should be assessed individually

SN Comprehens Clin Med 3(4):10311041 Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1